Cellebrite DI Ltd. Files Amendment No. 1 to Annual Report on Form 20-F

TL;DR

<b>Cellebrite DI Ltd. has filed an amendment to its 2023 annual report, providing updated information and confirming its listing on the Nasdaq Global Market.</b>

AI Summary

Cellebrite DI Ltd. (CLBT) filed a Amended Foreign Annual Report (20-F/A) with the SEC on April 12, 2024. Cellebrite DI Ltd. filed an amendment (No. 1) to its annual report on Form 20-F for the fiscal year ended December 31, 2023. The filing was made on April 12, 2024. The company's ordinary shares trade on the Nasdaq Global Market under the symbol CLBT. As of March 11, 2024, Cellebrite had 205,297,065 ordinary shares outstanding. The report indicates that Cellebrite is not a well-known seasoned issuer.

Why It Matters

For investors and stakeholders tracking Cellebrite DI Ltd., this filing contains several important signals. This amendment to the 20-F filing may contain updated financial information, risk factors, or other disclosures that could impact investor understanding of the company's performance and outlook. The confirmation of outstanding share count and trading information is crucial for investors assessing liquidity and market capitalization.

Risk Assessment

Risk Level: low — Cellebrite DI Ltd. shows low risk based on this filing. The filing is an amendment to a routine annual report and does not appear to contain significant new negative information, suggesting a low immediate risk.

Analyst Insight

Investors should review the specific changes made in Amendment No. 1 to the 20-F filing for any material updates to Cellebrite's financial or operational status.

Key Numbers

• 205,297,065 — Ordinary Shares Outstanding (As of March 11, 2024)
• 2023-12-31 — Fiscal Year End (Covered by the annual report)
• 2024-04-12 — Filing Date (Date of Amendment No. 1 filing)

Key Players & Entities

• Cellebrite DI Ltd. (company) — Filer name
• CLBT (company) — Trading symbol
• Nasdaq Global Market (company) — Exchange where securities are registered
• 205,297,065 (dollar_amount) — Number of ordinary shares outstanding as of March 11, 2024
• 94 Shlomo Shmelzer Road (company) — Principal executive offices address
• Petah Tikva (company) — City of principal executive offices
• Israel (company) — Jurisdiction of incorporation

FAQ

Industry Context

Cellebrite operates in the software services industry, specifically focusing on digital intelligence solutions.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, requiring annual reports from foreign private issuers.

What Investors Should Do

1. Review Amendment No. 1 to Form 20-F for specific changes and disclosures.
2. Monitor future filings for updated financial and operational performance.
3. Verify share count and trading information for investment analysis.

Key Dates

• 2023-12-31: Fiscal Year End — Period covered by the annual report
• 2024-04-12: Filing Date — Date of Amendment No. 1 filing
• 2024-03-11: Ordinary Shares Outstanding Date — Date for which share count is reported

Year-Over-Year Comparison

This is an amendment to the previously filed annual report, indicating updates or corrections to the original submission.

Key Financial Figures

• $30.00 — t reflects a typographical change from "$30.00" to "$17.50" in (i) the third paragraph
• $17.50 — typographical change from "$30.00" to "$17.50" in (i) the third paragraph of the Risk
• $195 million — For example, our revenue has grown from $195 million in 2020 to $325 million in 2023, and ou
• $325 million — has grown from $195 million in 2020 to $325 million in 2023, and our headcount has increase

Filing Documents

• ea0203730-20fa1_celleb.htm (20-F/A) — 474KB
• ea020373001ex12-1_cellebrite.htm (EX-12.1) — 11KB
• ea020373001ex12-2_cellebrite.htm (EX-12.2) — 12KB
• ea020373001ex13-1_cellebrite.htm (EX-13.1) — 7KB
• ea020373001ex13-2_cellebrite.htm (EX-13.2) — 7KB
• 0001213900-24-032611.txt (&nbsp;) — 865KB
• clbt-20231231.xsd (EX-101.SCH) — 4KB
• clbt-20231231_def.xml (EX-101.DEF) — 20KB
• clbt-20231231_lab.xml (EX-101.LAB) — 40KB
• clbt-20231231_pre.xml (EX-101.PRE) — 21KB
• ea0203730-20fa1_celleb_htm.xml (XML) — 9KB

KEY INFORMATION

ITEM 3. KEY INFORMATION 1

MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS

ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 42 PART III

EXHIBITS

ITEM 19. EXHIBITS 45

SIGNATURES

SIGNATURES 47 i PART I ITEM 3. KEY INFORMATION A. [Reserved] B. Capitalization and Indebtedness Not applicable. C. Reasons for the Offer and Use of Proceeds Not applicable. D.

Risk Factors

Risk Factors An investment in our securities involves a high degree of risk. You should carefully consider the risks described below before making an investment decision. Our business, prospects, financial condition, or operating results could be harmed by any of these risks, as well as other risks not known to us or that we consider immaterial as of the date of this Annual Report. The trading price of our securities could decline due to any of these risks, and, as a result, you may lose all or part of your investment. Risks Related to Cellebrite's Business and Industry If we do not continue to develop new and technologically advanced solutions and enhance our products, our future revenue, financial and operating results would be negatively affected. Cellebrite offers a comprehensive suite of digital investigative, or DI, solutions that includes a variety of solutions designed to help our customers collect, review, analyze and manage investigative data with respect to legally sanctioned investigations. We specialize in the creation of software based solutions that enable collection, decoding, decryption, analysis, reporting, review and management of data derived from digital sources manufactured or produced by a variety of original equipment manufacturers ("OEMs") as well as the applications installed on such sources. Because OEMs and other software manufacturers are continuously changing their products, our success depends on our ability to design and develop new solutions and upgrades to our existing software solutions that keep up with these changes. To remain competitive, we must continue to develop new offerings, as well as features and enhancements to our existing solutions. Maintaining adequate research and development personnel and resources to meet the demands of the market is essential. However, there can be no assurance that we are able to design and develop adequate solutions and upgrades that will be compatible with products from OEMs and other

View Full Filing

View this 20-F/A filing on SEC EDGAR